A domestic producer coalition filed petitions on March 31 with the Commerce Department and the International Trade Commission requesting new antidumping duty investigations on mattresses from Cambodia, Indonesia, Malaysia, Serbia, Thailand, Turkey and Vietnam, and new countervailing duties on mattresses from China. Commerce will now decide whether to begin AD/CVD investigations on mattresses from these countries that could eventually result in the assessment of AD/CV duties.
CBP will add on April 2 the ability in ACE for importers to file entries with recently excluded goods in the fourth tranche of Section 301 tariffs, it said in a CSMS message. The fourth tranche product exclusions apply retroactively to Sept. 1, 2019, and will remain in effect until Sept. 1, 2020. (see 2003260030)
International Trade Today is providing readers with some of the top stories for March 23-27 in case they were missed.
CBP issued the following releases on commercial trade and related matters:
CBP added on March 31 the ability in ACE for importers to file entries with recently excluded goods in the third tranche of Section 301 tariffs, it said in a CSMS message. The official Office of the U.S. Trade Representative notice for the exclusions was published on March 26 (see 2003230043). The exclusions are in subheading 9903.88.43. The exclusions are available for any product that meets the description in the Annex to USTR’s notice, regardless of whether the importer filed an exclusion request. The product exclusions apply retroactively to Sept. 24, 2018, and will expire after Aug. 7, 2020. The CSMS message also includes a summary of Section 301 duties that shows information on each tranche of tariffs and granted product exclusions.
CBP may still suspend some duty collections (see 2003280001), according to a person knowledgeable about the discussions. The Wall Street Journal said in a March 27 report that duty collections would be deferred for three months, though President Donald Trump called the report “fake news.” The person said that there are multiple options being looked at and the plans are not yet finalized. One such option includes limiting the deferrals to regular duties, taxes and fees, and not trade remedies, such as the Section 301 tariffs and antidumping or countervailing duties, the person said. While the specifics are still being discussed, the action may come in the form of an executive order or Federal Register notice, the person said.
CBP may still suspend some duty collections, according to a person knowledgeable of the discussions. The Wall Street Journal said in a March 27 report that duty collections would be deferred for three months, though President Donald Trump called the report "fake news."
The House of Representatives, on a voice vote March 27, passed a bill that will give businesses access to forgivable loans and grants to keep operations going as the economy grinds to a halt due to the novel coronavirus COVID-19 pandemic. President Donald Trump signed it later that afternoon. It includes a provision that could help importers that have been unprofitable after the imposition of Section 301 or Section 232 tariffs (see 2003250025). Companies can use the losses they incurred in 2018, 2019 or 2020 to get income tax refunds from the previous five years. They could apply now for those 2018 and 2019 losses. The bill also sets in motion a study of the U.S. medical product supply chain.
The Office of the U.S. Trade Representative issued another set of product exclusions from the fourth group of Section 301 tariffs on goods from China. The new exclusions from the tariffs include "five 10-digit HTSUS subheadings and seven specially prepared product descriptions, which together cover 36 separate exclusion requests." according to the notice. The product exclusions apply retroactively to Sept. 1, 2019, the date the fourth set of tariffs took effect. The exclusions will remain in effect until Sept. 1.
The Senate Finance Committee chairman, joined by 11 other Senate Republicans, is asking President Donald Trump to consider a total moratorium on new or raised tariffs, as well as examining how tariffs and import and export restrictions specific to medical supplies can be tackled. They praised the Office of the U.S. Trade Representative for excluding some medical supplies from Section 301 tariffs since the novel coronavirus COVID-19 pandemic spread to the U.S., but said a wider review should be done to make sure none remain. And they encouraged him to coordinate with other countries that have imposed export restrictions in response to COVID-19, so that there aren't cost increases and “critical supply shortages.”